UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 2,600 shares, a growth of 1,200.0% from the March 31st total of 200 shares. Based on an average daily trading volume, of 24,200 shares, the short-interest ratio is presently 0.1 days.

UCB Trading Up 3.9 %

OTCMKTS:UCBJY traded up $2.51 during mid-day trading on Thursday, hitting $67.30. 31,930 shares of the company’s stock traded hands, compared to its average volume of 12,260. The company has a fifty day moving average of $59.36 and a 200 day moving average of $47.89. UCB has a twelve month low of $34.85 and a twelve month high of $67.30.

UCB Cuts Dividend

The company also recently declared a dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 29th will be paid a dividend of $0.4574 per share. The ex-dividend date is Friday, April 26th. This represents a yield of 0.71%. UCB’s payout ratio is presently 46.55%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.